Anxiety and panic are the most common adverse effects of cannabis intoxication; reactions potentiated by stress. Data suggest that cannabinoid (CB 1 ) receptor modulation of amygdalar activity contributes to these phenomena. Using Fos as a marker, we tested the hypothesis that environmental stress and CB 1 cannabinoid receptor activity interact in the regulation of amygdalar activation in male mice. Both 30 min of restraint and CB 1 receptor agonist treatment (D 9 -tetrahydrocannabinol (2.5 mg/kg) or CP55940 (0.3 mg/kg); by i.p. injection) produced barely detectable increases in Fos expression within the central amygdala (CeA). However, the combination of restraint and CB 1 agonist administration produced robust Fos induction within the CeA, indicating a synergistic interaction between environmental stress and CB 1 receptor activation. An inhibitor of endocannabinoid transport, AM404 (10 mg/kg), produced an additive interaction with restraint within the CeA. In contrast, fatty acid amide hydrolase (FAAH) inhibitor-treated mice (URB597, 1 mg/kg) and FAAH À/À mice did not exhibit any differences in amygdalar activation in response to restraint compared to control mice. In the basolateral (BLA) and medial amygdala, restraint stress produced a low level of Fos induction, which was unaffected by cannabinoid treatment. Interestingly, the CB 1 receptor antagonist SR141716 dose-dependently increased Fos expression in the BLA and CeA. These data suggest the CeA is an important neural substrate subserving the interactions between cannabinoids and environmental stress, and could be relevant to understanding the context-dependent emotional and affective changes induced by marijuana intoxication and the role of endocannabinoid signaling in the modulation of amygdalar activity.
INTRODUCTION
The subjective effects of cannabis intoxication include euphoria, relaxation and impaired cognition, and, under certain circumstances, anxiety, panic, and overt psychosis (Abel, 1971; Szuster et al, 1988; Adams and Martin, 1996; Thomas, 1996; Degenhardt et al, 2001) . Data suggest that some of these effects are dependent upon environmental context, basal levels of anxiety, and previous drug experience (Jones, 1971; Carlin et al, 1972; Szuster et al, 1988) . In particular, adverse reactions such as anxiety and panic induced by cannabis are more common in drug-naïve subjects and in novel or stressful environmental situations. For example, D
9
-tetrahydrocannabinol (THC)-induced anxiety reactions in humans are potentiated by oral surgery procedures and during cognitive tasks accompanied by experimenter harassment (Gregg et al, 1976; Naliboff et al, 1976) . Consistent with these observations, the most common reasons given for cessation of cannabis use are anxiety and panic reactions (symptoms reported in as much as 20% of subjects); however, the most common reasons given for continued cannabis use in long-term users are relaxation and reduced tension (Szuster et al, 1988; Thomas, 1996; Reilly et al, 1998) . These data suggest that appropriate modulation of cannabinoid systems could have anxiolytic actions in humans. Although adverse anxiety and panic reactions severely limit the clinical utility of direct CB 1 agonists, recent preclinical data suggest that pharmacological modulation of endogenous cannabinoid (eCB) systems could represent a novel approach to the treatment of anxiety-related neuropsychiatric disorders (Marsicano et al, 2002; Kathuria et al, 2003) .
Consistent with human data, dose-and environmentdependent effects of cannabinoids have also been reported in the animal literature. Low doses of THC and synthetic cannabinoids produce anxiolytic effects in laboratory rodents, whereas higher doses produce anxiety-like behaviors and activation of the hypothalamic-pituitary-adrenocortical axis (Manzanares et al, 1999; Giuliani et al, 2000; Berrendero and Maldonado, 2002; Marin et al, 2003) . In addition, the expression of anxiety-like behaviors and associated biochemical alterations induced by THC are facilitated by exposure to novel or stressful environments (Ng et al, 1973; MacLean and Littleton, 1977) . Taken together, these data suggest strong interactions among cannabinoids, anxiety, and environmental stress; however, the neural substrates subserving these interactions have only begun to be explored (MacLean and Littleton, 1977; Onaivi et al, 1995; McGregor et al, 1998) .
Anatomical, cellular, and functional evidence suggests that the amygdala plays a key role in emotional and affective changes experienced during cannabis intoxication, and could contribute to the interaction of cannabinoids with environmental stressors. The basolateral complex of the amygdala (BLA) receives and integrates sensory information from the cortex and thalamus, and under appropriate circumstances can activate specific output structures including the central nucleus of the amygdala (CeA) (Davis, 2002; Sah et al, 2003) . Projections from the CeA to hypothalamic and brainstem structures contribute to the behavioral and physiological activation associated with emotionally salient environmental stimuli (Davis, 2002) . High levels of CB 1 cannabinoid receptors are expressed by a subset of cholecystokinin (CCK)-positive GABAergic interneurons within the BLA (McDonald and Mascagni, 2001) . CB 1 receptors are also expressed by BLA pyramidal neurons, but at lower levels (McDonald and Mascagni, 2001) . CB 1 receptors have also been reported within the CeA, but neurochemical characterization within this region is lacking (Matsuda et al, 1993; Tsou et al, 1998) . Activation of CB 1 receptors within the BLA decreases both GABAergic and glutamatergic neurotransmission via presynaptic inhibition of neurotransmitter release (Katona et al, 2001; Azad et al, 2003) . However, CB 1 activation in the CeA does not modulate GABAergic transmission, and effects on glutamatergic transmission have not been studied (Katona et al, 2001) . Similarly, no data regarding the cellular effects of cannabinoids within the medial amygdala (MeA) are available. Functionally, it has been shown that systemic administration of CB 1 agonists induces robust Fos expression within the CeA (McGregor et al, 1998; Arnold et al, 2001) , and direct injection of THC into this region produces anxiety-like responses in mice (Onaivi et al, 1995) . Although complex, the role of CB 1 receptor activation in the modulation of amygdalar circuitry provides a framework from which predictions can be made regarding the mechanisms by which cannabinoids affect emotional processes.
Based on the prominent role of CB 1 receptor activity in the inhibition of GABAergic transmission within the BLA, Katona et al (2001) have proposed that activation of CB 1 receptors results in increased activity of BLA principal projection neurons, which initiates an increase in the activity of their efferent targets, including CeA neurons. They hypothesize that this mechanism could account for the anxiety-like behaviors and robust CeA activation associated with cannabinoid administration. Since the activity of BLA pyramidal neurons is tightly regulated by local GABAergic transmission Quirk and Gehlert, 2003) , and CB 1 agonists attenuate GABAergic neurotransmission, an extension of this hypothesis is that cannabinoids effectively reduce the threshold at which salient sensory stimuli activate the BLA-CeA pathway (Katona et al, 2001) . Such a mechanism could account for the finding that subthreshold environmental stress or even normally neutral stimuli can acquire emotional or affective salience during cannabis intoxication.
In this study, we tested the hypothesis that cannabinoid administration modulates amygdalar activation in response to mild environmental stress. Our results indicate that cannabinoid agonists can interact synergistically with salient environmental stimuli to facilitate CeA activation. These data support a role for the CeA in the interactions between cannabinoids and stress. In addition, these findings shed light on the role of eCB signaling in the modulation of amygdalar activity in vivo and could have implications for the development of eCB-based therapeutics for anxietyrelated disorders.
METHODS

Drugs and Animals
Male, ICR mice (21-24 g) were used in most experiments (Harlan, Madison, WI). For one experiment, male wild-type (WT, C57/BL6) and FAAH À/À mice derived from homozygous breeders were used (Cravatt et al, 2001) . All animals were housed on a 12 : 12 light/dark cycle with lights on at 0600. Animals had ad lib access to food and water. All experiments were carried out in accordance with the NIH Guide for the Use and Care of Laboratory Animals.
AM404 was purchased from Tocris Cookson (Ellisville, MO). SR141716 and THC were provided by the NIDA Drug Supply Program (Research Triangle Park, NC). CP55940 was a gift from Pfizer Central Research (Groton, CT). URB597 was purchased from Cayman Chemical (Ann Arbor, MI). All drugs, except URB597, were dissolved in emulphor vehicle (18 : 1 : 1, saline : emulphor : ethanol), and delivered by i.p. injection in a volume of 10 ml/kg. URB597 was dissolved in DMSO and delivered in a volume of 50 ml by i.p. injection.
Restraint Procedure and Tissue Preparation
Animals were acclimated to the testing room 24 h prior to experimentation. Mice were restrained for 30 min in modified transparent 50 ml plastic conical tubes with numerous small air holes to increase ventilation; control animals were left undisturbed in their home cage. One end of the conical tube was closed using the screw top, while the other end was removed and a tight gauze plug inserted after the animals were placed inside. Animals were placed on the bench top for the restraint period. Drugs were administered at given times prior to restraint (see Figure 1 for schematic depiction of experimental protocol). The direct CB 1 receptor agonists THC (2.5 mg/kg) and CP55940 (0.3 mg/ kg) and the CB 1 receptor antagonist SR141716 (5 mg/kg) were administered 30 min prior to restraint. AM404 has low affinity for CB 1 receptors, but inhibits neuronal transport of the eCBs N-arachidonylethanolamine (AEA) and 2-arachidonylglycerol (2-AG) (Beltramo et al, 1997; Beltramo and Piomelli, 2000) and inhibits catabolism of AEA by fatty acid amide hydrolase (FAAH) (Jarrahian et al, 2000) . AM404 (10 mg/kg) was administered 90 min prior to restraint stress to allow for the accumulation of extraneuronal eCBs (Giuffrida et al, 2000) . We administered the irreversible FAAH inhibitor, URB597 (1 mg/kg), 90 min prior to restraint, a time point at which brain AEA content is elevated (Kathuria et al, 2003) . We used a maximal dose of URB597 to minimize the possibility of a false negative result.
After 30 min of restraint, animals were placed back in their home cage for 2 h, at which time they were anesthetized with isoflurane, and perfused transcardially with 10 ml PBS, followed by 20 ml of 4% formaldehyde. After perfusion, brains were removed and incubated in 30% sucrose for 48 h. Frozen sections (35 mm thick) were cut on a cryostat and stored in an ethylene glycol solution at -201C until processed for immunohistochemistry.
Fos Expression Studies
For quantitative studies, Fos-like immunoreactive (Fos-li) neurons were detected using a rabbit anti-c-Fos antibody (Oncogene, Cambridge, MA; 1 : 25 000 dilution) and the immunohistochemical protocol described previously (Patel and Hillard, 2003) . Sections were counterstained with toluidine blue to assist with identification of amygdalar subnuclei. For double-labeled anatomical studies, a goat anti-c-Fos antibody (Santa Cruz Biotechnology, Santa Cruz, CA; 1 : 1000 dilution) was used in combination with the rabbit anti-CB 1 antibody raised against the N-terminal 77-amino-acid residues of the CB 1 receptor (Affinity Bio Reagents, Golden, CO; 1 : 100 dilution) (Tsou et al, 1998) . Reaction products for Fos and CB 1 immunoreactivity (CB 1 -ir) were visualized using appropriate biotin-conjugated secondary antibodies (1 : 500 dilution; Jackson Immunoresearch, West Grove, PA) followed by processing with the ABC kit (Vector Labs, Burlingame, CA) with Ni/Co heavy metal intensification to yield a black nuclear reaction product for Fos, and plain DAB to yield brown reaction product for CB 1 -ir. For double-labeled fluorescence experiments, a streptavidin-conjugated Alexa 488 (Molecular Probes, Eugene, OR; 1 : 500 dilution) was used to yield a fluorescent signal for Fos, while glutamic acid decarboxylase 67 (GAD 67) immunoreactivity was detected using a mouse anti-GAD 67 antibody (Chemicon, Temecula, CA; 1 : 2000 dilution), followed by 2 h incubation in goat antimouse CY3-conjugated secondary antibody (1 : 500 dilution; Jackson Immunoresearch).
For quantitative analysis, bright-field photomicrographs from matched coronal sections were obtained for each region of interest using a Nikon Eclipse E600 microscope and SPOT advanced imaging software (see Figure 2 for schematic depiction of anatomical regions analyzed). All sections from a given experiment were obtained during the same microscopy session at which the light level and camera exposure times were kept constant. This was performed to minimize variability in the automated cellcounting procedure. The numbers of Fos-li cells within the BLA, MeA, and CeA were determined. A diagram depicting the regions from which cell counts were obtained is shown in Figure 2 . Photomicrographs were opened in Image J (available online from the NIH) for automated cell counting. Images were converted to 8-bit mono, each region (BLA, CeA, and MeA) was outlined with the freehand draw tool, and the number of Fos-li nuclei was determined within the specified region using the threshold and particle analysis functions of Image J. Particles that met both optical density and size requirements were automatically counted as Fos-li. Figure 1 Schematic diagram of experimental protocol used in drug pretreatment studies. All experiments included four groups (n ¼ 4-5/ group): vehicle-control (V-C), animals injected with vehicle at the same pretreatment time as the appropriate drug and left in their home cage until perfusion; drug-control (D-C), animals injected with drug and left in their home cage until perfusion; vehicle-restraint (V-R); animals injected with vehicle at the same pretreatment time as the appropriate drug, restrained for 30 min, and returned to their home cage for 2 h, then perfused; drugrestraint (D-R), animals treated with drug and exposed to restraint, returned to their home cage for 2 h, and then perfused. The black rectangle represents restraint exposure. Specific drugs were administered at time points prior to restraint as indicated. Figure 2 Schematic diagram of the anatomical regions used for automated cell counting. The BLA, MeA, and CeA were outlined as shown using the freehand draw tool of Image J and separate cell counts were obtained from each region.
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Data Analysis
Since the number of Fos-li cells in control animals varied somewhat between individual experiments, statistical analyses were confined to comparisons between control and treated animals from the same experiment and immunohistochemical procedure. For each region, data were analyzed by two-way ANOVA factoring restraint condition (control or restrained) and drug treatment (vehicle or drug). When significant main effects of restraint or drug were observed, post hoc Dunnett's test was applied to determine significant differences from the vehicle-control (V-C) group. For the SR141716 dose-response experiment, data were analyzed by one-way ANOVA followed by post hoc Dunnett's test. A po0.05 was considered to be significant throughout. Data are presented as mean7SEM number of Fos-li neurons; individual data points are also shown in all figures.
RESULTS
Anatomical Description of CB 1 Receptors and Restraint-Induced Fos Expression within the Amygdala CB 1 -ir was detected within the BLA, MeA, and CeA (Figure 3a and b). Intensely stained CB 1 -positive fibers were observed surrounding cell bodies within the BLA. High CB 1 expressing cells that colocalized with GAD 67 were also observed within the BLA, indicating CB 1 expression by GABAergic interneurons (not shown). Low levels of cytoplasmic CB 1 staining were also observed within BLA pyramidal neurons (not shown). Within the CeA, only light, diffuse staining was observed, which appeared on very fine neuronal processes (see Figure 3a) . A similar pattern was observed in the MeA, with the exception that occasionally, intensely labeled beaded fibers were seen in this region (not shown). In general, this description is almost identical to that observed using this antibody in rats (Tsou et al, 1998) , and similar to studies using a C-terminal antibody in rats and mice (Katona et al, 2001) ; the major difference is the detection of immunoreactivity within the CeA using the N-terminal but not Cterminal antibody. All staining was eliminated by removal of primary antibody from the incubations.
To explore the interactions between environmental stress and cannabinoids in the activation of the amygdala, we utilized a threshold stimulus, 30 min of restraint, in combination with drug doses that produced little or no effect on Fos expression alone. In general, 30 min of restraint consistently increased the number of Fos-li neurons within the BLA and MeA, but not CeA (see Figure  3a and b, and below), indicating that the stimulus was sufficient to increase BLA and MeA activity, but was not of sufficient intensity or duration to increase CeA activity. The distribution of restraint-induced Fos expression within the amygdala can be seen in Figure 3a -c. Double-labeling studies indicate that cells expressing Fos in response to restraint stress within the BLA were not high CB 1 expressing ( Figure 3b) ; however, Fos-li neurons within BLA were found to receive perisomatic contacts from CB 1 -ir fibers (see Figure 3b ). Additional double-labeling studies indicate that restraint did not induce Fos expression within GAD Restraint did not increase the number of Fos-li cells within the CeA. In the absence of restraint, neither THC nor CP55940 significantly increased the number of Fos-li cells within the CeA compared to vehicle-treated control animals (Figures 4 and 5) . However, in contrast to the BLA and MeA, pretreatment with THC or CP55940 significantly and Figure 6 .
Effects of eCB Transport Inhibitor AM404 on Restraint-Induced Fos Expression
To explore whether eCBs contribute to stress-induced Fos expression within the amygdala, the eCB transport inhibitor AM404 was administered prior to restraint stress. Restraint increased the number of Fos-li cells within the BLA, whereas AM404 alone had no effect ( Figure 7) . Neither restraint nor AM404 alone significantly increased the number of Fos-li cells within the CeA. In contrast to the BLA and MeA, pretreatment with AM404 significantly potentiated restraint-induced Fos expression within the CeA (Figure 7) . Two-way ANOVA revealed a significant effect of restraint (F (1,15) ¼ 15.25, p ¼ 0.0014) and drug (F (1,15) ¼ 14.18, p ¼ 0.0019), and a significant interaction (F (1,15) ¼ 6.00, p ¼ 0.027). Although these data indicate an interaction between AM404 and restraint stress in the induction of Fos, the magnitude of this effect was far less than that seen with direct agonists. In addition, cells expressing Fos in response to the combination of AM404 and restraint were restricted to the capsular division of the CeA.
Effects of FAAH Inhibition on Restraint-Induced Fos Expression
We determined whether pharmacological or genetic inhibition of FAAH activity interacted with restraint stress to induce Fos expression within the amygdala. URB597 is not soluble in the emulphor vehicle used in all other studies and was therefore delivered in a small volume of DMSO. Intraperitoneal administration of DMSO alone increased Fos expression within the amygdala compared to emulphorinjected animals, consistent with its caustic properties in vivo. However, compared to vehicle-treated animals, URB597 did not increase Fos expression within the BLA Mice lacking FAAH exhibit elevated endogenous AEA, but not 2-AG, levels, thus representing a genetic model of enhanced AEA signaling (Cravatt et al, 2001) . We compared the effects of restraint stress on amygdalar Fos expression between FAAH À/À and WT mice. In accord with our pharmacological data, no significant difference in restraintinduced Fos expression within either the BLA or CeA was observed between WT and FAAH À/À mice (Figure 9 ). For the BLA, two-way ANOVA revealed a significant effect of restraint (F (1,12) 
Effects of the CB 1 Receptor Antagonist SR141716 on Restraint-Induced Fos Expression
To explore whether tonic eCB signaling modulates amygdalar activity, we treated mice with the CB 1 receptor antagonist SR141716 (5 and 10 mg/kg) 2 h before perfusion.
SR141716 produced a dose-dependent increase in Fos expression within the BLA and CeA (Figure 10 ). For the BLA, one-way ANOVA revealed a significant effect of To determine whether there is an interaction between restraint stress and eCB signaling, we pretreated animals with the CB 1 receptor antagonist SR141716 (5 mg/kg) 30 min prior to restraint. Restraint significantly increased the number of Fos-li cells within the BLA and MeA, but not CeA. SR141716 alone did not increase the number of Fos-li cells within the BLA, MeA, or CeA. SR141716 pretreatment significantly affected restraint-induced Fos expression within the BLA but did not significantly affect restraint-induced Fos expression within the CeA or MeA (Figure 11 and Table 1 ). For the BLA, two-way ANOVA revealed a significant effect of restraint (F (1,16) 
DISCUSSION
In order to detect a positive interaction between stress and cannabinoids, efforts were made to choose a stressor that produced a threshold level of Fos expression within the amygdala. Based on preliminary studies, we utilized 30 min of restraint. This stimulus produced a consistent activation of the BLA and MeA, but not CeA. Similarly, pilot doseresponse studies were used to select doses of drugs that produced little, if any, activation of the amygdala. This combination of stimuli resulted in the detection of synergistic interactions between environmental stress and CB 1 receptor agonists in the activation of CeA, but not BLA or MeA, as indexed by a robust induction of Fos protein.
Our data also indicate that augmentation of AEA signaling is not sufficient to recapitulate the effects of direct CB 1 agonists on Fos expression within the CeA, a finding that could be relevant to the development of eCB-based therapeutics for anxiety-related disorders. Lastly, our data with SR141716 indicate that tonic CB 1 receptor activation inhibits amygdalar activity under nonstressed conditions.
In general, our data are consistent with the model proposed by Katona et al (2001) that CB 1 agonists inhibit BLA GABAergic neurotransmission, which effectively reduces the threshold for activation of the BLA-CeA pathway by salient sensory stimuli. First, consistent with previous studies (Katona et al, 2001) , CB 1 -ir neurons within the BLA were found to be GABAergic, based on colocalization with GAD 67, supporting the role of CB 1 receptors in the modulation of GABAergic transmission. Second, neurons that expressed Fos in response to restraint were found to receive perisomatic contacts from CB 1 -ir fibers, providing an anatomical substrate which is consistent with an effect of CB 1 receptor activity on the activation of BLA neurons. Third, our functional data indicate that threshold aversive environmental stimuli induce robust activation of CeA neurons when combined with threshold doses of direct CB 1 receptor agonists. That blockade of CB 1 receptors during restraint moderated restraint-induced Fos expression within the BLA also supports this hypothesis. Since the restraint responsive neurons within the BLA were determined to be pyramidal projection neurons (based on a lack of colocalization with the GABAergic neuronal marker GAD67), we conclude that CB 1 receptor activation decreases the threshold at which salient stimuli activate the BLA-CeA pathway in vivo.
However, one aspect of the model proposed by Katona et al is not supported by the present results. The model predicts that stress-induced neuronal activation in the BLA should also be potentiated by CB 1 receptor activation, a finding not consistently observed in this study. Several methodological and theoretical possibilities could account for this difference. Methodological issues relate primarily to the use of immediate early gene expression as a marker of neuronal activation. It is possible that the activity of BLA neurons is increased by the combination of cannabinoid agonists and restraint, but the increase is not sufficient to induce detectable Fos expression. Alternatively, neurons that express Fos in response to restraint alone could be more active when restraint is combined with cannabinoid agonist administration, but since these cells would already have been counted as Fos-li, no further increase in the number of Fos-li neurons would be observed.
A more likely explanation is that the assumption of the original model, that the sole site of action of the cannabinoids is the BLA, is not correct. For example, cannabinoid actions within the CeA itself could result in potentiation of stress-induced activation of the CeA. This hypothesis is supported by the presence of CB 1 receptors within the CeA (present data; see also Matsuda et al, 1993; Tsou et al, 1998) and the ability of direct injections of THC into CeA to induce anxiety responses in mice (Onaivi et al, 1995) . Although the lack of effect of CB 1 receptor activation on GABAergic transmission within this region argues against this possibility (Katona et al, 2001 ), the precise role of CB 1 receptor activation in the modulation of CeA neuronal activity remains to be determined.
Another possibility is that CB 1 agonist potentiation of stress-induced CeA activation involves a trans-synaptic mechanism. For example, GABAergic cells within intercalated cell masses (ICM), which lie at the anatomical interface of the BLA and CeA, generate feedforward inhibition of CeA neurons in response to BLA activation (Royer et al, 1999 (Royer et al, , 2000 , and are regulated by extrinsic glutamatergic afferents from the prefrontal cortex and dopaminergic afferents from the ventral midbrain (Bissiere et al, 2003; . Therefore, cannabinoid actions within these regions, which are known to occur (French et al, 1997; Gessa et al, 1998; Auclair et al, 2000; Patel and Hillard, 2003) , could modulate CeA activity independently of the BLA, via modulation of ICM neuronal activity. Determining the contributions of these potential mechanisms to the effects observed in this study remains an important future goal.
Several issues regarding the pharmacological aspects of the present study also warrant discussion. The in vivo potency difference between THC and CP55940 in the activation of Fos expression within the CeA (less than 10-fold) is far less than that predicted by the differences in binding affinity for CB 1 receptors (about an 80-fold difference) (Hillard et al, 1995) . THC has lower efficacy at CB 1 receptor activation compared to CP55940 (Kearn et al, 1999) , which further suggests that in vivo differences between THC and CP55940 do not correlate with in vitro pharmacological properties. It is possible that the high affinity and efficacy of CP55940 result in robust receptor internalization and desensitization (Hsieh et al, 1999) . In contrast, the relatively low affinity and efficacy of THC could result in less internalization/desensitization and, therefore, be more likely to support continuous receptor signaling. The present data are at odds with those of Arnold et al (2001) in which 0.25 mg/kg CP55940 produced a robust increase in CeA Fos expression in rats. By contrast, we detected Fos expression within the CeA at 0.3 mg/kg CP55940 only when mice were also exposed to restraint. The differences between these results could be attributed to species used; alternatively, the present findings suggest that the rats in the former study were stressed, in addition to cannabinoid-treated. This notion is supported by the fact that the rats in the former study were exposed to behavioral tests and body temperature measurements before perfusion for Fos immunohistochemistry.
We also explored whether augmentation of eCB content interacted with restraint stress in the activation of the amygdala. AM404, administered at a time and dose known to increase AEA content in plasma (Giuffrida et al, 2000) , potentiated restraint-induced Fos expression within the CeA, although the magnitude of this increase was far less than that produced by direct CB 1 receptor agonists. In contrast, the FAAH inhibitor URB597, administered at a time and dose shown to increase brain AEA content and reduce FAAH activity (Kathuria et al, 2003) , did not alter restraint-induced Fos expression within the BLA or CeA. In addition, FAAH À/À mice, which exhibit highly elevated brain AEA content (Cravatt et al, 2001) , did not exhibit a potentiated amygdalar response to restraint compared to WT mice. Taken together, these data strongly suggest that complete lack of FAAH activity, and the associated elevation in AEA content, is not sufficient to mimic the effects of direct CB 1 agonists or AM404. This dissociation between FAAH inhibition and CB 1 receptor activation on restraintinduced CeA activity could be relevant to the monophasic, dose-dependent anxiolytic actions of URB597, compared to the biphasic effects of direct cannabinoid agonists on anxiety (Kathuria et al, 2003) . Lastly, it is possible that the selective interaction between AM404 and restraint stress, compared to FAAH inhibition, arises from the ability of AM404 to inhibit re-uptake of both AEA and 2-AG, since neither URB597 (Kathuria et al, 2003) nor genetic deletion of FAAH affects brain 2-AG content (unpublished data). In other words, it is possible that the eCB that mediates the effects of AM404 in this assay is 2-AG, not AEA. Another possibility is that the effects of AM404 are mediated via activation of vanilloid VR1 receptors, as it is an agonist of these receptors (Lastres-Becker et al, 2003) .
The effects of SR141716 on amygdalar neuronal activity are paradoxical in the light of the effects of CB 1 agonists. SR141716 produced a dose-dependent increase in Fos expression within the BLA and CeA, suggesting that eCB tone suppresses amygdala activity, an effect observed within other limbic regions such as the prefrontal cortex and nucleus accumbens (Alonso et al, 1999; Duarte et al, 2004) .
At least two possibilities could explain the effects of SR141716 on amygdalar activation. First, since CB 1 receptor activation has been shown to decrease glutamatergic transmission within the BLA (Azad et al, 2003) , SR141716-induced blockade of eCB tone could result in increased glutamatergic transmission, activation of BLA and, subsequently, CeA neurons. This suggestion, however, is not supported by anatomical data, since asymmetrical synapses within the BLA very rarely express CB 1 receptors detected using a C-terminal antibody (Katona et al, 2001) . Alternatively, since CB 1 receptors are located on CCKpositive interneurons within the BLA (McDonald and Mascagni, 2001) , and activation of CB 1 receptors can inhibit CCK release from hippocampal slices (Beinfeld and Connolly, 2001 ), SR141716-induced blockade of eCB tone could result in increased CCK release within the BLA. Since intraamygdala injections of CCK can induce anxiety-like behaviors (Belcheva et al, 1994) , and systemic administration of CCK increases Fos expression within the CeA (Day et al, 1994) , a CCK-dependent mechanism could subserve the amygdala-activating effects of SR141716 in rodents.
In conclusion, our data clearly support a role for increased CeA activity in the interactions between CB 1 receptor agonists and environmental stress, and suggest that eCB signaling tonically suppresses the activity of the BLA-CeA pathway under nonstressed conditions. These findings are generally consistent with the known cellular effects of CB 1 receptor activation within the amygdala. The CeA integrates amygdalar, thalamic, cortical, and brainstem inputs, and projects to limbic, hypothalamic, and autonomic targets. Therefore, we suggest the CeA could be an important neural substrate relevant to the context-dependent autonomic, affective, and emotional effects of cannabis intoxication in humans.
